JeKo-1 Xenograft Model Overview
The JeKo-1 xenograft model is derived from a human mantle cell lymphoma (MCL) cell line obtained from the peripheral blood of a patient with relapsed stage IV disease. This model retains key features of classical MCL, including the t(11;14)(q13;q32) chromosomal translocation and cyclin D1 overexpression, and is widely employed in preclinical studies evaluating therapeutic strategies targeting B-cell malignancies. JeKo-1 xenografts provide a robust, reproducible system for modeling the biology of MCL and testing novel agents that interfere with cell cycle progression, B-cell receptor (BCR) signaling, and apoptotic resistance mechanisms. Given its high translational fidelity, the JeKo-1 model is a cornerstone in drug development for mantle cell lymphoma.
Request a Custom Quote for JeKo‑1 Xenograft ModelBiological and Molecular Characteristics
JeKo-1 cells exhibit a mature B-cell immunophenotype characterized by expression of CD19, CD20, CD5, and surface immunoglobulin M (sIgM). The hallmark t(11;14) translocation results in dysregulated expression of cyclin D1, which drives uncontrolled G1/S cell cycle transition. The cells also display elevated levels of BCL2, contributing to resistance to apoptosis, and show activation of PI3K/AKT and NF-κB signaling pathways. These molecular features align with treatment vulnerabilities in MCL and render the model highly responsive to agents targeting CDK4/6, BCR signaling, and anti-apoptotic proteins.
| Characteristic | Description |
|---|---|
| Tissue Origin | Human mantle cell lymphoma (relapsed, leukemic phase) |
| Genetic Alteration | t(11;14)(q13;q32), cyclin D1 overexpression |
| Immunophenotype | CD19+, CD20+, CD5+, sIgM+, HLA-DR+ |
| Key Pathways | PI3K/AKT, NF-κB, BCL2 overexpression |
| Therapeutic Relevance | CDK4/6 inhibitors, BTK inhibitors, BCL2-targeted therapies |
In Vivo Model Development and Tumorigenicity
The JeKo-1 xenograft model is typically established by subcutaneous injection of tumor cells into immunodeficient mouse strains, such as NSG or NOD/SCID. Tumors are generally palpable within two to three weeks post-injection, with consistent growth reaching 500–900 mm³ by six to eight weeks. The model shows high tumor take rates and exhibits homogeneous growth kinetics across cohorts. Its reproducibility and alignment with clinical MCL biology make it highly suitable for longitudinal studies of drug efficacy, resistance profiling, and biomarker validation in a controlled in vivo setting.
Request a Custom Quote for JeKo‑1 Xenograft ModelHistopathology and Immunohistochemical Profile
JeKo-1 xenografts are composed of intermediate-sized lymphoid cells with irregular nuclear contours, inconspicuous nucleoli, and scant cytoplasm. Hematoxylin and eosin staining reveals diffuse sheets of neoplastic B cells without follicular architecture, typical of aggressive MCL. Immunohistochemical analyses show strong nuclear staining for cyclin D1 and membranous expression of CD20 and CD5. High levels of BCL2 and a Ki-67 proliferation index ranging from 40% to 70% are commonly observed, confirming active cell proliferation and apoptotic resistance. These histological features closely mirror those seen in human mantle cell lymphoma specimens.
Preclinical Applications and Drug Response
The JeKo-1 xenograft model has been extensively used to evaluate the efficacy of agents such as ibrutinib (BTK inhibitor), venetoclax (BCL2 antagonist), and palbociclib (CDK4/6 inhibitor), either as monotherapies or in combination. Due to its intact BCR signaling and cyclin D1-driven proliferation, the model is particularly effective for exploring mechanistic interactions among survival, cell cycle, and immune pathways. It is also employed in resistance modeling and translational research aimed at overcoming therapeutic limitations observed in clinical MCL cases. The JeKo-1 model provides a reliable and disease-relevant platform for preclinical studies targeting mantle cell lymphoma.
Request This Model
To request the JeKo-1 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for JeKo‑1 Xenograft Model